Lupin 2024

guaifenesin/pseudoephedrine tablets

Actavis, Perrigo to release store-brand Mucinex D

DUBLIN, Ireland — Actavis plc and Perrigo Co. plc have been cleared by the Food and Drug Administration to market guaifenesin/pseudoephedrine tablets, an expectorant. The companies said Tuesday that Perrigo is slated to commence shipments to U.S. retail and wholesale customers in time for the cough/cold season. The product will be packaged and marketed under

PP_1170x120_10-25-21